التفاصيل البيبلوغرافية
| العنوان: |
Table_1_Novel targeted inhibition of the IL-5 axis for drug reaction with eosinophilia and systemic symptoms syndrome.docx |
| المؤلفون: |
Limor Rubin, Aviv Talmon, Yaarit Ribak, Asa Kessler, Yossi Martin, Tal Keidar Haran, Oded Shamriz, Irit Adini, Yuval Tal |
| سنة النشر: |
2023 |
| المجموعة: |
Frontiers: Figshare |
| مصطلحات موضوعية: |
Immunology, Applied Immunology (incl. Antibody Engineering, Xenotransplantation and T-cell Therapies), Autoimmunity, Cellular Immunology, Humoural Immunology and Immunochemistry, Immunogenetics (incl. Genetic Immunology), Innate Immunity, Transplantation Immunology, Tumour Immunology, Immunology not elsewhere classified, Genetic Immunology, Animal Immunology, Veterinary Immunology, drug reaction with eosinophilia and systemic symptoms (DRESS), interleukin (IL), monoclonal antibodies (mAbs), IL-5 antibody, biotherapeutic agent |
| الوصف: |
Background The drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome represents a severe hypersensitivity reaction. Up-to-date treatment is based on withdrawal of medication, supportive care, and immunosuppression using high-dose corticosteroid (CS) therapy. However, evidence-based data are lacking regarding second-line therapy for steroid-resistant or steroid-dependent patients. Objectives We hypothesize that the interleukin (IL)-5 axis plays a critical role in the pathophysiology of DRESS; hence, inhibition of this signaling pathway could offer a potential therapy for steroid-dependent and/or steroid-resistant cases, and it may offer an alternative to CS therapy in certain patients more prone to CS toxicity. Methods Herein, we collected worldwide data on DRESS cases treated with biological agents targeting the IL-5 axis. We reviewed all cases indexed in PubMed up to October 2022 and performed a total analysis including our center experience with two additional novel cases. Results A review of the literature yielded 14 patients with DRESS who were treated with biological agents targeting the IL-5 axis as well as our two new cases. Reported patients are characterized by a female-to-male ratio of 1:1 and a mean age of 51.8 (17–87) years. The DRESS-inducing drugs, as expected from the prospective RegiSCAR study, were mostly antibiotics (7/16), as follows: vancomycin, trimethoprim-sulfamethoxazole, ciprofloxacin, piperacillin-tazobactam, and cefepime. DRESS patients were treated with anti-IL-5 agents (mepolizumab and reslizumab) or anti-IL-5 receptor (IL-5R) biologics (benralizumab). All patients have clinically improved under anti-IL-5/IL-5R biologics. Multiple doses of mepolizumab were needed to achieve clinical resolution, whereas a single dose of benralizumab was often sufficient. Relapse was noted in one patient receiving benralizumab treatment. One patient receiving benralizumab had a fatal outcome, although mortality was probably related to massive bleeding and cardiac arrest due to ... |
| نوع الوثيقة: |
dataset |
| اللغة: |
unknown |
| العلاقة: |
https://figshare.com/articles/dataset/Table_1_Novel_targeted_inhibition_of_the_IL-5_axis_for_drug_reaction_with_eosinophilia_and_systemic_symptoms_syndrome_docx/22715605Test |
| DOI: |
10.3389/fimmu.2023.1134178.s002 |
| الإتاحة: |
https://doi.org/10.3389/fimmu.2023.1134178.s002Test
https://figshare.com/articles/dataset/Table_1_Novel_targeted_inhibition_of_the_IL-5_axis_for_drug_reaction_with_eosinophilia_and_systemic_symptoms_syndrome_docx/22715605Test |
| حقوق: |
CC BY 4.0 |
| رقم الانضمام: |
edsbas.8CF66A59 |
| قاعدة البيانات: |
BASE |
